1269477821_b802f3c7c5_c

Mylan issues recall for anxiety drug Xanax over contamination fears

pharmafile | October 29, 2019 | News story | Manufacturing and Production Mylan, anxiety, pharma, xanax 

Mylan has announced it has issued a recall of its anxiety therapy Xanax (alprazolam) over suspicions the drug could be contaminated with a “foreign substance” and pose a risk to patients.

The alert was made known via the FDA website and concerns the 0.5mg tablet formulation of the drug, made available throughout July and August this year in bottles of 500.

“Clinical impact from the foreign material, if present, is expected to be rare, but the remote risk of infection to a patient cannot be ruled out,” said Mylan in the notice. “To date, Mylan has not received any adverse events related to this batch.”

The drugmaker contacted wholesalers and retailers with instructions to return the affected product; consumers were also contacted in turn with similar instructions. Xanax is typically used for the management of anxiety disorder, and can provide relief for panic disorder.

Advertisement

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

blood_test

Johnson & Johnson announces successful results from trial for myeloma treatment

Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bend Bioscience adds commercial spray drying facility to Georgia site

Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …

The Gateway to Local Adoption Series

Latest content